What is the recommended treatment for proteinuria?

Treatment for Proteinuria

The cornerstone of proteinuria treatment is renin-angiotensin system (RAS) blockade with ACE inhibitors or ARBs, titrated to maximum tolerated doses, with the addition of SGLT2 inhibitors for patients with CKD and proteinuria >0.5 g/day. 1, 2

Initial Approach: Supportive Care Foundation

All patients with proteinuria require optimized supportive care before considering immunosuppression:

RAS Blockade Strategy

• Start ACE inhibitor or ARB (not both) when proteinuria exceeds 0.5 g/day 2, 1
• Uptitrate to maximum tolerated dose targeting proteinuria <1 g/day 3
• Monitor creatinine and potassium closely; accept up to 30% creatinine increase if stable 1
• Blood pressure targets:
  • <120 mm Hg systolic for most adults 1
  • <130/80 mm Hg if proteinuria <1 g/day
  • <125/75 mm Hg if proteinuria >1 g/day 3

Add SGLT2 Inhibitors

• Strongly recommended for patients with CKD and proteinuria, with or without diabetes 4, 2
• Provides additional kidney protection beyond RAS blockade alone
• Can be used with eGFR as low as 20 mL/min 2

Lifestyle Modifications (Essential Adjuncts)

• Sodium restriction to <2 g/day 1
• Weight normalization
• Smoking cessation
• Regular exercise

Disease-Specific Immunosuppression

IgA Nephropathy

Treatment algorithm based on proteinuria level after 3-6 months of optimized supportive care:

1. Proteinuria <0.5 g/day: Annual monitoring only 5

2. Proteinuria 0.5-1.0 g/day: Continue RAS blockade and SGLT2i; monitor closely 2

   • Note: Even this "low-grade" proteinuria increases kidney failure risk (HR 1.73-2.87) 6

3. Proteinuria >1 g/day despite 3-6 months optimized care AND eGFR >50 mL/min:

   • Add 6-month corticosteroid course 3
   • Regimen: IV methylprednisolone 1g x 3 days, then oral prednisone 0.8-1 mg/kg/day for 2 months, taper by 0.2 mg/kg/day monthly over next 4 months 3
   • This provides 10-year renal survival of 97% vs 53% without immunosuppression 3

4. eGFR <30 mL/min: Focus on RAS blockade, prepare for dialysis/transplant; reserve corticosteroids only for persistently increasing proteinuria 5

Lupus Nephritis

For Class III/IV (±V) disease:

• First-line induction: MMF 2-3 g/day OR low-dose IV cyclophosphamide (500 mg every 2 weeks x 6 doses) PLUS glucocorticoids 7
• Glucocorticoid regimen: IV methylprednisolone 500-2500 mg total, then oral prednisone 0.3-0.5 mg/kg/day, taper to ≤7.5 mg/day by 3-6 months 7
• Alternative for nephrotic-range proteinuria: MMF 1-2 g/day + tacrolimus 7
• Add hydroxychloroquine (≤5 mg/kg/day) to all regimens 7

For Pure Class V disease:

• If nephrotic-range proteinuria: MMF 2-3 g/day + pulse methylprednisolone followed by prednisone 20 mg/day (taper to ≤5 mg/day by 3 months) 7, 8
• Alternative: Tacrolimus or cyclosporine, especially with heavy proteinuria 8

Treatment targets:

• 25% proteinuria reduction by 3 months
• 50% reduction by 6 months
• UPCR <500-700 mg/g by 12 months (complete response) 7
• Patients with baseline nephrotic-range proteinuria may need additional 6-12 months 7

Membranous Nephropathy

Initiate immunosuppression only when:

• Nephrotic syndrome present AND at least one of:
  • Proteinuria persistently >4 g/day and remains >50% baseline despite 6 months of RAS blockade 9
  • Severe/disabling nephrotic symptoms 9
  • Creatinine risen ≥30% within 6-12 months with eGFR >25-30 mL/min 9

Treatment: 6-month course of alternating monthly cycles of oral/IV corticosteroids plus oral alkylating agents 9

Critical Monitoring Parameters

• Proteinuria: Monthly initially, then every 3 months
• Kidney function: Creatinine/eGFR every 2-4 weeks when initiating/adjusting RAS blockade
• Potassium: Every 2-4 weeks; use potassium-wasting diuretics or binders to maintain normal levels and continue RAS blockade 1
• Blood pressure: Every visit

Common Pitfalls to Avoid

1. Do NOT combine ACE inhibitor + ARB - increases adverse events (hyperkalemia, AKI) without additional benefit 10, 1

2. Do NOT stop RAS blockade prematurely for modest creatinine increases up to 30% if stable 1

3. Do NOT start RAS blockade in acute-onset nephrotic syndrome (especially minimal change disease) - risk of AKI 1

4. Do NOT rush to immunosuppression - allow 3-6 months of optimized supportive care first (except lupus nephritis) 3, 2

5. Counsel patients to hold RAS blockers during sick days with volume depletion risk 1

6. In lupus nephritis, do NOT switch therapy prematurely if proteinuria is improving, even if not yet at target - patients may take 12-24 months for complete response 7, 9

The treatment paradigm has evolved significantly: proteinuria <0.5 g/day is now the therapeutic goal across most glomerular diseases, as even "low-grade" proteinuria (0.5-1.0 g/day) predicts progressive kidney disease 6, 2. This requires aggressive but safe use of RAS blockade plus SGLT2 inhibitors as the foundation, with disease-specific immunosuppression added when supportive care alone is insufficient.